All In Biotech

Drug Trial Radar · NCT04322890

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.

Last checked: Nov 19, 2026Latest source record: Oct 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

6,000

Planned (sponsor's estimate)

Start

Apr 16, 2020

Primary completion

Dec 24, 2026

Study completion Dec 24, 2027

Sponsor

Lead sponsor
Hunan Province Tumor HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 26, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.

Conditions

  • Non Small Cell Lung Cancer
  • EGFR Gene Mutation
  • ALK Gene Mutation
  • ROS1 Gene Mutation
  • MET Gene Mutation

Interventions

  • OsimertinibDrug

    Osimertinib 80mg, po, qd;

  • Alectinib 150 MGDrug

    Alectinib 600mg, po, qd; Lorlatinib, 100mg, po, qd;

  • Crizotinib 250 MGDrug

    Crizotinib 250 MG po bid.

  • Savolitinib, Crizotinib.Drug

    Savolitinib, 300mg po qd.

  • ChemotherapyDrug

    500mg, ivgtt, every 21day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Time from first subject dose to study completion, or up to 36 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yongchang Zhang

    Changsha, Hunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.